| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Loss (gain) on sale of marketable investments | NaN | NaN | 18 |
| Net loss | 6,760 | -3,284 | -6,499 |
| Depreciation of property and equipment | -19 | 9 | 19 |
| Abandonment and expiration of patents and trademark rights | NaN | 82 | 615 |
| Amortization of patent, trademark rights | -105 | 45 | 94 |
| Equity-based compensation | NaN | 0 | 60 |
| Amortization of debt discount and other expenses | 183 | NaN | NaN |
| Gain on sale of marketable securities | NaN | 17 | NaN |
| Non-cash lease expense | 72 | -59 | -81 |
| Amortization of financial obligation | NaN | 69 | 183 |
| Loss (gain) on sale of marketable investments | -1 | NaN | NaN |
| Loss on change in fair value of warrant liability | 1,138 | -670 | NaN |
| Loss of issuance of warrants | 3,945 | -3,977 | 0 |
| Other receivables | -7 | NaN | NaN |
| Non-cash gain on settlement of liability | NaN | -3,041 | NaN |
| Other assets | 700 | 11 | -761 |
| Prepaid expenses and other current assets and other non-current assets | 127 | -24 | -9 |
| Funds receivable from new jersey net operating loss | NaN | NaN | 0 |
| Lease liability | 64 | -56 | -78 |
| Accounts payable | 1,241 | -2,570 | 914 |
| Accrued expenses | -223 | 287 | -33 |
| Net cash used in operating activities | 6,252 | -5,079 | -3,892 |
| Proceeds from sale of marketable securities | NaN | 296 | 2,026 |
| Proceeds from sale of marketable investments | 4 | NaN | NaN |
| Purchase of marketable securities | NaN | 0 | 91 |
| Purchase of marketable investments | 6 | NaN | NaN |
| (purchase) abandonment of patent and trademark rights | -248 | 0 | 283 |
| Net cash (used in) provided by investing activities | -1,985 | 296 | 1,652 |
| Proceeds from issuance of common stock and warrants | NaN | 7,314 | NaN |
| Proceeds from sale of stock, net of issuance costs | NaN | -398 | 765 |
| Proceeds from issuance of common stock, net of issuance costs | 2,001 | NaN | NaN |
| Proceeds from note payable, net of issuance costs | NaN | 0 | 250 |
| Proceeds from warrant exercise | 2,156 | NaN | NaN |
| Repayment of debt with cash | NaN | 660 | NaN |
| Repayment of debt obligation | 200 | NaN | NaN |
| Proceeds from issuance of equity warrants | NaN | NaN | 0 |
| Proceeds from equity line of credit | NaN | 398 | NaN |
| Proceeds from rights offering | 1,630 | NaN | NaN |
| Net cash provided by financing activities | -2,082 | 6,654 | 1,015 |
| Net increase (decrease) in cash and cash equivalents | 2,185 | 1,871 | -1,225 |
| Cash and cash equivalents at beginning of period | 2,347 | 1,701 | NaN |
| Cash and cash equivalents at end of period | 5,816 | 2,347 | NaN |
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)